Key Points
- Director Blake Borgeson sold 30,000 Recursion Pharmaceuticals shares at an average price of $3.34, generating $100,200. The sale was conducted under a pre-arranged Rule 10b5-1 plan and reduced his holdings by 0.48% to about 6.16 million shares.
- Recursion shares opened at $3.38, near their 50-day and 200-day moving averages of $3.33, with a market capitalization of approximately $1.81 billion. The company recently missed quarterly revenue and EPS expectations and remains unprofitable.
- Analyst sentiment is mixed, with the stock carrying a consensus “Hold” rating and an average price target of $8.06. Institutional investors own approximately 89.06% of the company, with Vanguard and State Street among the largest holders.
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Get Free Report) Director Blake Borgeson sold 30,000 shares of the firm's stock in a transaction dated Tuesday, September 1st. The stock was sold at an average price of $3.34, for a total value of $100,200.00. Following the transaction, the director owned 6,158,287 shares in the company, valued at approximately $20,568,678.58. This trade represents a 0.48% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Blake Borgeson also recently made the following trade(s):
- On Tuesday, August 4th, Blake Borgeson sold 30,000 shares of Recursion Pharmaceuticals stock. The shares were sold at an average price of $3.25, for a total value of $97,500.00.
- On Tuesday, July 7th, Blake Borgeson sold 40,000 shares of Recursion Pharmaceuticals stock. The stock was sold at an average price of $3.96, for a total transaction of $158,400.00.
Recursion Pharmaceuticals Stock Up 1.5%
Shares of NASDAQ:RXRX opened at $3.38 on Thursday. Recursion Pharmaceuticals, Inc. has a 52 week low of $2.77 and a 52 week high of $7.18. The company has a debt-to-equity ratio of 0.01, a quick ratio of 5.03 and a current ratio of 5.03. The company has a market capitalization of $1.81 billion, a PE ratio of -3.25 and a beta of 1.07. The company has a 50 day moving average price of $3.33 and a two-hundred day moving average price of $3.33.
Recursion Pharmaceuticals (NASDAQ:RXRX - Get Free Report) last announced its quarterly earnings results on Wednesday, August 5th. The company reported ($0.25) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.24) by ($0.01). The firm had revenue of $7.67 million during the quarter, compared to analyst estimates of $10.97 million. Recursion Pharmaceuticals had a negative net margin of 945.94% and a negative return on equity of 50.41%. During the same period last year, the firm earned ($0.41) EPS. Analysts forecast that Recursion Pharmaceuticals, Inc. will post -0.92 earnings per share for the current year.
Wall Street Analyst Weigh In
Several equities research analysts recently commented on RXRX shares. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Recursion Pharmaceuticals in a research report on Friday, July 17th. Wall Street Zen raised Recursion Pharmaceuticals from a "strong sell" rating to a "sell" rating in a research note on Saturday, August 29th. Morgan Stanley set a $5.30 price target on Recursion Pharmaceuticals in a report on Monday, August 17th. Finally, Needham & Company LLC reaffirmed a "buy" rating and set a $8.00 price objective on shares of Recursion Pharmaceuticals in a research report on Thursday, May 7th. Two investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of "Hold" and a consensus target price of $8.06.
Get Our Latest Stock Analysis on Recursion Pharmaceuticals
Institutional Investors Weigh In On Recursion Pharmaceuticals
Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Vanguard Group Inc. grew its holdings in shares of Recursion Pharmaceuticals by 18.6% in the 4th quarter. Vanguard Group Inc. now owns 47,187,759 shares of the company's stock valued at $192,998,000 after acquiring an additional 7,407,606 shares in the last quarter. State Street Corp raised its holdings in Recursion Pharmaceuticals by 38.7% during the fourth quarter. State Street Corp now owns 25,333,888 shares of the company's stock worth $103,616,000 after acquiring an additional 7,064,963 shares in the last quarter. Norges Bank bought a new stake in Recursion Pharmaceuticals during the fourth quarter worth about $23,473,000. ARK Investment Management LLC boosted its position in Recursion Pharmaceuticals by 11.2% during the fourth quarter. ARK Investment Management LLC now owns 37,316,856 shares of the company's stock valued at $152,626,000 after purchasing an additional 3,771,357 shares during the last quarter. Finally, Renaissance Technologies LLC bought a new position in Recursion Pharmaceuticals in the first quarter valued at approximately $7,370,000. 89.06% of the stock is currently owned by institutional investors and hedge funds.
Recursion Pharmaceuticals Company Profile
(
Get Free Report)
Recursion Pharmaceuticals, Inc (NASDAQ: RXRX) is a biopharmaceutical company that combines advanced automation, artificial intelligence and high-throughput biology to discover and develop novel therapeutics. The company's proprietary platform integrates deep-learning algorithms with large-scale cellular imaging and chemical biology, enabling the rapid identification of potential drug candidates across a range of indications. By automating complex laboratory workflows and leveraging computational models, Recursion aims to accelerate the drug discovery process and expand the scope of targets that can be addressed.
At the core of Recursion's offering is its digital biology platform, which captures billions of cell images under varying chemical and genetic perturbations.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
